Aims: For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target (area under the curve 400-700 mg h L −1 ). This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and nonobese individuals, in order to guide vancomycin dosing in the obese. Methods: Morbidly obese individuals (n = 20) undergoing bariatric surgery and nonobese healthy volunteers (n = 8; total body weight [TBW] 60.0-234.6 kg) received a single vancomycin dose (obese: 12.5 mg kg −1 , maximum 2500 mg; nonobese: 1000 mg) with plasma concentrations measured over 48 h (11-13 samples per individual). Modelling, internal validation, external validation using previously published data and simulations (n = 10.000 individuals, TBW 60-230 kg) were performed using NONMEM. Results: In a 3-compartment model, peripheral volume of distribution and clearance increased with TBW (both p < 0.001), which was confirmed in the external validation.
| INTRODUCTION
Over recent decades, the worldwide prevalence of obesity (defined as a body mass index [BMI] ≥30 kg m −2 ) has dramatically increased. 1 Since 1975, the percentage of obese men and women has increased from 3.2 and 6.4% to 10.8 and 14.9%, respectively. This corresponds with 641 million individuals being obese worldwide. If this trend continues, global obesity prevalence will reach 18-21% in 2025. 1 Evidence suggests that these individuals are more prone to infections. 2 As a consequence, clinicians are increasingly facing (severely) obese patients requiring antibiotic treatment. It has been well established that due to pathophysiological changes that are associated with overweight, such as an increased cardiac output, increase in adipose tissue, changes in renal function and impacted metabolic enzyme activity, the pharmacokinetics (PK) of drugs can be significantly impacted, often requiring dose adaptations. 3, 4 Vancomycin is a glycopeptide antibiotic, introduced in clinical practice over 60 years ago. Since then, vancomycin has become a widely used agent predominantly for serious Gram-positive infections and is considered first line treatment in methicillin-resistant Staphylococcus aureus infections. 5 For these indications, the drug is administered intravenously using intermittent or continuous infusion regimens, preceded by a loading dose in the latter setting. 6, 7 Around 80% is excreted unchanged renally, mostly by glomerular filtration but other (active) excretion pathways might also play an important role. 6 In S. aureus infections, vancomycin efficacy closely correlates with a total 24-h area under the curve (AUC 24h ) over the minimal inhibitory concentration (MIC). Target AUC 24h of vancomycin for efficacy for this indication have been well defined in the clinical setting, with thresholds of ≥345 to ≥451 mg h L −1 found over the years, based on MICs up to 1 mg L −1 . [8] [9] [10] [11] [12] A comprehensive practice guideline published in 2009 advocated an efficacy target of AUC 24h / MIC ≥400 mg h L −1 . 13 To reach this target with intermittent dose regimens, a target steady state trough concentration of 15-20 mg L −1 was advised. 13 There is, however, substantial evidence from other populations that lower trough concentration ranges might also be effective to reach the AUC 24h target. 14, 15 To date, this has not been studied for the obese population. Regarding vancomycin toxicity, 700 mg h L −1 was recently proposed as an AUC 24h upper limit for the first 48 h of treatment. 16 Another study found an increasing risk of nephrotoxicity with steady state AUC 24h values over 1300 mg h L −1 . 17 With respect to dosing guidelines, according to the Food and Drug Administration (FDA) drug label, vancomycin should be given as a fixed dose of 2000 mg day −1 in adults with a normal renal function, without specific recommendations for obese patients. 18 Since the FDA-regimen has been shown to result in suboptimal exposure (AUC 24h around 100-250 mg h L −1 ) in normal weight adults, more recent guidelines recommend 15-20 mg kg −1 every 8-12 h. 13 This rather broad dosing regimen is also recommended for obese patients, thereby resulting in a large variability of dose regimens used for obese individuals in clinical practice 13 and is based on studies that are mostly performed with sparse data based on routine therapeutic drug monitoring (TDM) peak and trough levels. [19] [20] [21] [22] [23] [24] Most of these studies show that both volume of distribution and clearance increase in obese patients. Initially, total body weight (TBW) was shown to be the best predictor for vancomycin clearance. 20, 21 However, these findings have been challenged by other studies conducted in obese patients, including the most recent. 19, 22, 24 As a consequence, the exact dosing strategy for vancomycin in obese patients still remains to be established. This study aims to quantify the PK of vancomycin in morbidly obese and nonobese individuals. Using prospectively collected, rich data gathered over 48 h after a single dose in individuals over a wide range in body weight, we aim to identify covariates that best predict changes in vancomycin clearance and volume of distribution in obesity. The model is externally validated using independent data and is ultimately applied to guide vancomycin dosing in the (morbidly) obese, thereby optimizing target attainment.
What is already known about this subject • Obesity can dramatically impact the pharmacokinetics of antibiotics due to pathophysiological changes associated with being overweight.
• For vancomycin, target 24-h area under the curve values for efficacy and toxicity have been well established for Staphylococcus aureus infections and have been incorporated in current guidelines.
• While there is ample evidence that both volume of distribution and clearance increase in obese individuals, there is conflicting evidence about how the vancomycin dose should exactly be adapted in obese patients.
What this study adds
• This prospective, rich sampling pharmacokinetic study in a wide range of body weights (60-235 kg) shows that vancomycin volume of distribution and clearance can be predicted by total body weight using a linear (volume of distribution) or a power function with an exponent of 0.54 (clearance).
• We recommend that in order to optimize exposure in obese individuals without renal impairment, vancomycin should be dosed as 35 mg kg −1 day −1 (maximized at 5500 mg day −1 ).
• When divided over 2 doses day −1 , trough concentrations between 5.7 and 14.6 mg L −1 are sufficient to obtain the target exposure.
• For continuous infusion regimens, we recommend a fixed loading dose of 1500 mg for all body weights.
| METHODS

| Subjects
Morbidly obese patients with an indication for bariatric surgery (BMI ≥40 kg m −2 or ≥35 kg m −2 with comorbidities), i.e. laparoscopic sleeve gastrectomy or gastric bypass, and nonobese healthy volunteers (BMI 18-25 kg m −2 ) were considered for inclusion in this study.
Participants were excluded when they were known to have an allergy to glycopeptides, were pregnant or breastfeeding, were renally impaired (defined as estimated glomerular filtration rate of <60 mL min −1 1.73 m −2 (calculated using the Cockcroft-Gault [CG] formula with lean body weight [LBW] for obese 25 
| Study design
| Sample assay
Vancomycin plasma concentrations were measured using a validated, commercially available immune-assay method (VANC3, Cobas System, Roche Diagnostics GmbH, Mannheim, Germany) with a limit of detection (LOD) of 1.5 mg L −1 , lower limit of quantification (LLOQ) of 4 mg L −1 and upper limit of quantification of 80 mg L −1 .
Measured concentrations below LOD or LLOQ were reported in the dataset. Within-run and interday variability was 3.7 and 4.4%, respectively. and Pearl-speaks-NONMEM 4.8.1 26 using Pirana 2.9.7 (Certara USA, Inc, Princeton, USA). 27, 28 One-, 2-and 3-compartmental models were evaluated with the ADVAN 1, 3 or 11 routine, respectively, using the first order conditional estimation method with interaction and addition of the LAPLACIAN method. Interindividual variability (IIV) and residual variability were assumed to be respectively lognormally and normally distributed. NONMEM output was visualized with R 3.5.1 (Xpose package 4.6.1) 29 and GraphPad Prism 6.0 (GraphPad Software, La Jolla, USA). Values below LOD were analysed using the M3 method as described elsewhere. 30 35 Inclusion was considered when step-by-step inclusion resulted in a drop in OFV of at least −3.84 (P < .05) and backward deletion gave an OFV increase of at least 10.8 points (P < .001). Furthermore, the contribution of a covariate was judged based on the reduction in IIV and diagnostics described earlier.
| PK analysis
| Internal validation
The final model was internally validated by pcVPC based on 1000 simulations, split for obese and nonobese individuals. Parameter precision and robustness of the structural and final model were analysed by the sampling importance resampling procedure. 36 
| External validation
Data from a previously published prospective study in which 6 obese (111-226 kg) and 4 nonobese (66-89 kg) individuals with normal renal function received a single infusion of 1000 mg vancomycin in 40 min, 21 were used to externally validate our PK (covariate) model. In the external validation study, vancomycin concentrations were measured using a validated immuno-assay with a LLOQ of 0.5 mg L −1 . External validation was done using pcVPC based on 1000 simulations, split for obese and nonobese individuals. Bias and precision of the model was quantified by calculation of the median prediction error (MPE) and root mean squared error (RMSE) according to equations (1) and (2),
where PE i and RMSE are the prediction error for the ith observation and root mean squared error of all observations, where C pred,i and C obs,i represent the predicted and observed vancomycin concentration for the ith observation and N is total number of observations. MPE under 20% and RMSE under 5 mg L −1 were considered accurate.
| Simulation based comparison of dosing strategies
To guide the optimal dosing strategy in the obese, simulations using the Figure A1 in the appendix.
| PK analysis
A 3-compartment model with first order elimination and a combined proportional and additive residual error model with IIV for clearance, V1 and V2 best described the data. Parameters of the structural model are shown in Table 2 .
Implementation of TBW with a linear relationship on V2 gave the largest reduction in OFV (−24.5; P < .001) and IIV (from 37.1 to 5.8%). In the model with TBW on V2, IIV on V2 was omitted from the model since this did not impact the OFV (+0.11). In the following step, the best results were obtained by inclusion of (1) CL, clearance; V1, volume of distribution of central compartment; V2, volume of distribution of peripheral compartment 2; V3, volume of distribution of peripheral compartment 3; Q V1-V2 , intercompartmental clearance between V1 and V2; Q V1-V3 , intercompartmental clearance between V1 and V3; TBW, total body weight; OFV, objective function value; RSE, relative standard error based on covariance step in NONMEM; 95% CI, 95% confidence interval obtained from sampling importance resampling procedure.
LBW and ABW-models. Since TBW is more readily available in clinical practice and is therefore preferable in the light of model-informed dose recommendations, we chose to include TBW on clearance. Inclusion of MDRD, CKD-EPI, CG-TBW, CG-LBW or GFR (based on 24-h creatinine clearance) did not significantly improve the model (P > .001). After inclusion of TBW on clearance, no remaining covariates could be identified for this parameter. Lastly, introduction of age as covariate on V1 and V2 resulted in a decrease of OFV with −19.4 points and improved GOF (P < .001).
Since IIV for clearance appeared to be significantly higher in the obese group, we estimated separate IIV values for both groups, resulting in an OFV drop of −11.8 and a resulting IIV on clearance of 5.3% and 24.7% for nonobese and obese subpopulations, respectively.
While the IIV on clearance in the nonobese showed a high uncertainty and significant shrinkage, we decided to fix this parameter to 5.3% in the final model, since removing it from the model resulted in a penalty of 4 points increase in OFV. The final PK parameters of the resulting model are shown in Table 2 . GOF plots for the final model are shown in Figure A2 .
| Internal validation
The pcVPC, shown in Figure 1 shows that the median and 2.5 th and 97.5 th percentiles of the prediction intervals correspond with the observations. The lower panel in Figure 1 shows that the model performs well in predicting the portion of observations that are below LOD. Confidence intervals of the model parameters based on the sampling importance resampling procedure are presented in Table 2 .
| External validation
The pcVPCs of the external validation using data of the study from Blouin and colleagues (6 obese and 4 nonobese individuals) are shown in Figure 2 . The VPC shows a good predictive performance of our Figure 3 shows the results of simulations in obese individuals ranging 90-230 kg upon weight-based dose regimens. In Figure 3 , the left column shows the resulting mean AUC 24h with 95% percentiles, while in the right column PTA (AUC 24h > 400) and PTOX (AUC 24h > 700) at day 3 are presented. Figure A3 in the appendix shows the same plot for fixed dose regimens. Figure 3 shows that when the vancomycin dose is increased from 25 mg kg −1 day −1 to 45 mg kg −1 day −1 , both chances of achieving an AUC 24h > 400 and > 700 increase for all individuals. A high PTA could be achieved for all body weights using a dose regimen of 35 mg kg −1 day −1 , maximized at 5500 mg day −1 . 
| Simulation based comparison of dosing strategies
| Correlation of trough concentrations with achievement of target AUC 24h
A daily dose of 35 mg kg −1 , maximized at 5500 mg day −1 , was selected for simulation of trough concentrations at day 3 when given as intermittent or continuous infusion regimens. Figure 5 shows the AUC 24h vs trough concentrations for obese individuals at day 3. There is a strong relationship between AUC at day 3 and trough concentrations, 
| DISCUSSION
Our study shows that vancomycin PK is significantly altered by obesity. We found that in obese individuals up to 235 kg without renal impairment, vancomycin clearance could be predicted by TBW ( A strong aspect of our study is the prospective study design with intensive PK sampling in adults with a wide range of body weights across the included cohort from 60 to 235 kg, allowing for the characterisation of a 3-compartment model. This is in contrast with other reports on vancomycin PK in obesity, that fully rely on TDM data, that consist mostly of peak and trough concentrations, making it difficult to estimate >1 compartment, thereby limiting the ability to adequately assess individual PK parameters. 19, 22 Moreover, we used data from a previously performed study to externally validate our model. 21 Our model showed a high precision without bias in describing the data in the obese subgroup. Therefore, taken these results together with our internal validation, we can conclude that our PK-model shows an excellent performance in predicting vancomycin PK in the (morbidly) obese population up to 235 kg.
Our results on vancomycin clearance and volume of distribution in obese individuals puts forward what was known on vancomycin PK in obesity. Regarding clearance, predominantly retrospective studies also found a larger vancomycin clearance in obese compared to nonobese individuals. 19, 20, 22, 24 One prospective rich sampling PK study in healthy obese individuals, similar to our study design but with only 6 in our study. 21 One retrospective study in 108 obese and 596 nonobese patients, found no difference in absolute vancomycin clearance between both groups. 23 24 or a combination of serum creatinine, age, TBW and sex. 22 These results might be explained by differences in studied body weights or employed sampling schedules (i.e. use of TDM data vs intensive sampling). Considering the fact that vancomycin is predominantly excreted renally, it is interesting that we found TBW to be a better predictor than any of the renal function estimates including GFR based on 24-h urine clearance. This might be explained by the lack of individuals with renal impairment in our study. In addition, in our PK model vancomycin clearance of a typical individual of 70 kg is 5.72 L h −1 , corresponding to 95 mL min −1 , which is slightly below the average GFR in our relatively young population. This is in line with what has been reported in other studies and suggests that other processes besides glomerular filtration also play a role. 6 There is substantial evidence that obesity can influence both passive and active processes in the kidneys, 37 which might explain why body weight is a better predictor for vancomycin clearance than renal function estimates in obese individuals without renal failure.
Results on vancomycin volume of distribution in obese seem to be more consistent across literature. Five studies reported on changes in volume of distribution, all describing an increase of volume of distribution with body weight in a linear fashion. [19] [20] [21] 23, 24 No study reported age as a covariate for volume of distribution. In our study we found age as covariate for volume of distribution, even though its impact was limited. As a consequence, increasing age does not impact the proposed dose regimen.
It is well known that vancomycin PK exhibits large IIV and has a small therapeutic window, and therefore the 2009 consensus guideline recommends that TDM is routinely applied when treating patients with vancomycin. 13 Our results further substantiate this recommendation for the obese populations, since our final PK model still shows considerable unexplained IIV for both clearance (25% in the obese subgroup) and volume of distribution (45% on V1). To obtain an adequate AUC 24h between 400 and 700 mg h L −1 , guidelines recommend to target trough concentrations between 15-20 mg L −1 . 13 We show that in obese individuals, steady state trough concentrations of 5.7--14.6 mg L −1 (when dosed 2 times daily) are sufficient to assure adequate exposure. This discrepancy with the guideline recommendation has been reported for several other special populations as well. 14, 15 Plots with individual posthoc clearance and volume of distribution values visualized by colour (shown in Figure A5 in the appendix) point out that the variability in volume of distribution explains why we see this range in trough concentrations with similar AUC 24 values. To circumvent this problem in translating trough concentrations to exposure, it might be preferable to measure the AUC directly using a limited sampling strategy (for example with peak-and-trough concentrations) along with the employment of Bayesian forecasting software.
This recommendation has also been incorporated in the revision of the 38 If resources or knowledge is unavailable, clinicians should be aware that in obese individuals, trough concentrations below 15 mg L −1 do not necessarily correspond to a subtherapeutic exposures and therefore do not always require dose adjustments.
Some limitations apply to our study. First, our participants received only a single vancomycin infusion. Therefore, extension of our PK model to simulate continuous infusions should be done with caution.
However, the maintenance dose is merely dependent on vancomycin clearance which can be adequately estimated in the current study design. Second, in interpreting the simulations, we chose a target PTA of 90% for selection of the best dose regimen, as advocated by the EMA. 39 However, certain situations may call for a higher target PTA and therefore a higher dosage, for example in serious lifethreatening infections. 39, 40 In addition, the target for PTA (AUC 24 > 400 mg h L −1 ), has only been established for S. aureus infections. We still remain fairly ignorant as to the appropriate targets for other infections where vancomycin is indicated. Third, obese individuals underwent bariatric surgery during the PK study, which could theoretically interfere with the results. However, the concerning operations are performed laparoscopically, with a short duration (<1 h), and minimal blood loss (<50 mL). Therefore, we consider this influence to be negligible. Last, the participants in our study were, besides being obese, otherwise healthy individuals with adequate renal function. Therefore, one should apply caution in extrapolating of our results to individuals with renal impairment or critical illness and always perform TDM in these populations.
In conclusion, our study shows that in order to obtain optimal exposure with minimal risk on toxicity, vancomycin should be dosed as 35 mg kg −1 day −1 in obese individuals without renal impairment. For continuous infusion regimens, a loading dose of 1500 mg is sufficient for the whole population to obtain steady state at day 1. 
